Arbutus Biopharma Corpora... (ABUS)
NASDAQ: ABUS
· Real-Time Price · USD
3.08
-0.04 (-1.28%)
At close: May 16, 2025, 3:59 PM
3.22
4.38%
After-hours: May 16, 2025, 04:45 PM EDT
Arbutus Biopharma Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|
| License Revenue | 2.56M | 10.7M | 26M | 4.67M | 3.4M |
| License Revenue Growth | -76.06% | -58.85% | +456.15% | +37.70% | n/a |
| Non-Cash Royalty Revenue | 2.25M | 3.87M | 7.65M | 6.11M | n/a |
| Non-Cash Royalty Revenue Growth | -41.76% | -49.47% | +25.29% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 5.83M | 4.71M | 4.54M | 7.19M | 4.96M | 4.74M | 5.84M | 5.98M | 5.55M | 4.25M | 3.49M | 5.2M | 4.89M | 4.7M | 4.15M | 4.45M | 3.85M | 3.54M | 4.07M | 3.57M | 3.55M | 1.88M | 3.25M | 8.19M | 4.41M | 5.93M | 2.63M | 3.77M | 3.67M | 3.54M | 3.66M | 4.6M | 4.33M | 4.73M | 3.72M | 23.77M | 7.22M | 8.35M | 7.71M | 7.7M | 2.72M |
| Selling, General, and Administrative Revenue Growth | +23.77% | +3.86% | -36.91% | +45.07% | +4.53% | -18.83% | -2.31% | +7.71% | +30.67% | +21.64% | -32.83% | +6.30% | +4.13% | +13.31% | -6.73% | +15.54% | +8.67% | -12.92% | +13.99% | +0.37% | +89.29% | -42.23% | -60.32% | +85.61% | -25.56% | +125.28% | -30.30% | +2.89% | +3.56% | -3.17% | -20.44% | +6.26% | -8.56% | +27.23% | -84.35% | +229.21% | -13.59% | +8.41% | +0.08% | +183.51% | n/a |
| Research and Development Revenue | 8.96M | 8.81M | 14.27M | 15.55M | 15.4M | 17.56M | 20.17M | 17.69M | 18.27M | 22.95M | 20.05M | 22.94M | 18.46M | 20.44M | 16.3M | 15.4M | 13.37M | 14.54M | 12.06M | 10.46M | 10.42M | 12.42M | 17.73M | 12.74M | 14.71M | 11.06M | 16.57M | 16.36M | 13.95M | 17.82M | 15.54M | 15.45M | 13.87M | 17.16M | 15.74M | 15.21M | 13.14M | 14.9M | 16.35M | 9.7M | 10.56M |
| Research and Development Revenue Growth | +1.69% | -38.28% | -8.22% | +0.96% | -12.30% | -12.92% | +14.00% | -3.19% | -20.37% | +14.43% | -12.58% | +24.27% | -9.66% | +25.39% | +5.87% | +15.15% | -8.02% | +20.47% | +15.29% | +0.47% | -16.12% | -29.96% | +39.18% | -13.40% | +32.98% | -33.22% | +1.28% | +17.26% | -21.73% | +14.71% | +0.60% | +11.34% | -19.14% | +9.01% | +3.44% | +15.76% | -11.81% | -8.87% | +68.60% | -8.12% | n/a |